312 related articles for article (PubMed ID: 32209699)
1. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.
Stalnecker CA; Der CJ
Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699
[TBL] [Abstract][Full Text] [Related]
2. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
3. The role of wild type RAS isoforms in cancer.
Zhou B; Der CJ; Cox AD
Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
[TBL] [Abstract][Full Text] [Related]
4. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
5. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
6. Emerging strategies to target RAS signaling in human cancer therapy.
Chen K; Zhang Y; Qian L; Wang P
J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
[TBL] [Abstract][Full Text] [Related]
7. The renewed battle against RAS-mutant cancers.
Zhang F; Cheong JK
Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
[TBL] [Abstract][Full Text] [Related]
8. The Role of Wild-Type RAS in Oncogenic RAS Transformation.
Sheffels E; Kortum RL
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33924994
[TBL] [Abstract][Full Text] [Related]
9. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
10. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations.
Burge RA; Hobbs GA
Adv Cancer Res; 2022; 153():29-61. PubMed ID: 35101234
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
13. Biochemical And Tumorigenic Effects Of Redox Modification Of Ras-G12c By Nitric Oxide.
Crowe M
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162270
[TBL] [Abstract][Full Text] [Related]
14. Ral-specific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth.
Goi T; Rusanescu G; Urano T; Feig LA
Mol Cell Biol; 1999 Mar; 19(3):1731-41. PubMed ID: 10022860
[TBL] [Abstract][Full Text] [Related]
15. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
16. How to make an undruggable enzyme druggable: lessons from ras proteins.
Sayyed-Ahmad A; Gorfe AA
Adv Protein Chem Struct Biol; 2020; 122():181-202. PubMed ID: 32951811
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
18. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
19. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
